SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with anIC5o of 0.39 uM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. which can improve bioavailability and half-life when administered orally[1.

Product information

CAS Number: 22203-98-1

Molecular Weight: 282.12

Formula: C13H9Cl2NO2

Chemical Name: 5-chloro-N-(3-chlorophenyl)-2-hydroxybenzamide

Smiles: OC1=CC=C(Cl)C=C1C(=O)NC1=CC(Cl)=CC=C1

InChiKey: NXDGLRGDIKDWIF-UHFFFAOYSA-N

InChi: InChI=1S/C13H9Cl2NO2/c14-8-2-1-3-10(6-8)16-13(18)11-7-9(15)4-5-12(11)17/h1-7,17H,(H,16,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

Products are for research use only. Not for human use.